Xconomy Seattle

Dendreon May Open Atlanta Plant

Eric Hal Schwartz7/17/09

Dendreon, the Seattle-based cancer drug developer, may open a new manufacturing plant in Georgia, according to a report in the Atlanta Business Chronicle. Dendreon’s product, a new drug to treat prostate cancer, is being reviewed for approval by the FDA. Xconomy has written about Dendreon’s limited manufacturing before. The possible plant could cost $80 million and create more than 300 jobs in Atlanta. Currently, Dendreon has a commercial manufacturing plant in Morris Plains, NJ.

Eric Hal Schwartz was an intern in Xconomy's Seattle office.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

Links to This Post

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.